Physician profile
Amy D Ames
NPI 1467964940
$43,255.34
in general payments reported to CMS, 2019-2025
18 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $342 · 2022: $415 · 2023: $20K · 2024: $22K · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Consulting Fee: $11K · Travel and Lodging: $3,725 · Food and Beverage: $2,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,500.00 |
| Consulting Fee | $11,062.50 |
| Travel and Lodging | $3,724.96 |
| Food and Beverage | $2,210.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $41,401.37 | 2022-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $401.62 | 2021-2024 | Jornay Pm |
| Corium, LLC | $321.76 | 2022-2025 | Azstarys |
| Alkermes, INC. | $188.08 | 2021-2025 | Lybalvi |
| Lundbeck LLC | $181.72 | 2021-2025 | Rexulti |
| Corcept Therapeutics | $100.00 | 2021 | |
| Supernus Pharmaceuticals, INC. | $96.33 | 2023-2024 | Qelbree, Qelbree |
| Abbvie INC. | $93.08 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.19 | 2021-2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $71.71 | 2025 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $57.28 | 2021-2023 | Nuedexta |
| Noven Therapeutics, LLC | $44.65 | 2024 | Xelstrym, Secuado |
| Owp Pharmaceuticals, INC. | $44.58 | 2022-2024 | Subvenite, Lamotrigine |
| Adlon Therapeutics L.P. | $38.95 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $38.94 | 2023 | Austedo, Austedo Xr |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $36.15 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.48 | 2021 | |
| Tempus Ai, INC | $22.45 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Ames listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.